Bone Loss in Rheumatoid Arthritis: Basic Mechanisms and Clinical Implications

被引:0
作者
Jae-hyuck Shim
Zheni Stavre
Ellen M. Gravallese
机构
[1] University of Massachusetts Medical School,Division of Rheumatology, Department of Medicine
来源
Calcified Tissue International | 2018年 / 102卷
关键词
Osteoclasts; Osteoblasts; Rheumatoid arthritis; Synovitis; Erosions;
D O I
暂无
中图分类号
学科分类号
摘要
Patients with rheumatoid arthritis (RA) have historically developed progressive damage of articular bone and cartilage, which correlates with disability over time. In addition, these patients are prone to periarticular and systemic bone loss, carrying additional morbidity. In contrast to what is seen in many other rheumatic diseases, the impact of inflammation on bone in RA is uniquely destructive. Loss of articular bone (erosions) and periarticular bone (demineralization) is a result of excessive bone resorption and markedly limited bone formation. There has been tremendous progress in preventing net bone loss in RA with the advent of disease-modifying agents, including biologic agents and small molecules, that both limit inflammation and may have a direct impact on the prevention of cytokine- and antibody-driven osteoclastogenesis. However, repair of existing bone erosions, although feasible, is observed infrequently. Lack of repair is a consequence of suppression of osteoblast function and bone formation by some of the same mechanisms that promote osteoclastogenesis and bone resorption. As new agents are introduced to control inflammation in RA, and novel mechanisms to target synovitis are identified, it may be possible in the future to fully repair damaged bone.
引用
收藏
页码:533 / 546
页数:13
相关论文
共 1077 条
  • [91] van Steenbergen HW(2012)Intrinsic danger: activation of Toll-like receptors in rheumatoid arthritis Rheumatology 51 7-1210
  • [92] Ajeganova S(2011)Expression of Toll-like receptors and their signaling pathways in rheumatoid synovitis J Rheumatol 38 810-3329
  • [93] Forslind K(2017)TLRs, future potential therapeutic targets for RA Autoimmun Rev 16 103-2579
  • [94] Svensson B(2012)TLR5, a novel and unidentified inflammatory mediator in rheumatoid arthritis that correlates with disease activity score and joint TNF-alpha levels J Immunol 189 475-997
  • [95] vander Helm-van AHM(2013)Apoptosis-associated uncoupling of bone formation and resorption in osteomyelitis Front Cell Infect Microbiol 3 101-250
  • [96] Mustila A(2014)Activated macrophage survival is coordinated by TAK1 binding proteins PLoS ONE 9 e94982-1009
  • [97] Korpela M(2002)Stimulation by toll-like receptors inhibits osteoclast differentiation J Immunol 169 1516-20
  • [98] Haapala AM(2014)Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis Ann Rheum Dis 73 516-1897
  • [99] Kautiainen H(2016)Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis BMJ 353 i1777-796
  • [100] Laasonen L(2012)A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial Arthritis Rheumatol 64 2824-142